» Articles » PMID: 23391324

Circulating MiR-150 and MiR-342 in Plasma Are Novel Potential Biomarkers for Acute Myeloid Leukemia

Abstract

Background: MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes, pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up has not been done yet.

Methods: TaqMan miRNA microarray was performed to identify deregulated miRNAs in the plasma of AML patients. Quantitative real-time RT-PCR was used to validate the results. Receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s).

Results: The plasma expression level of let-7d, miR-150, miR-339, and miR-342 was down-regulated whilst that of let-7b, and miR-523 was up-regulated in the AML group at diagnosis compared to healthy controls. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119- 0.9581; P<0.0001) and 0.8125 (95% CI: 0.6796-0.9454; P=0.0005) for miR-150, and miR-342 respectively. Combined ROC analyses using these 2 miRNAs revealed an elevated AUC of 0.86 (95% CI: 0.7819-0.94; P<0.0001) indicating the additive effect in the diagnostic value of these 2 miRNAs. QRT-PCR results showed that the expression level of these two miRs in complete remission AML patients resembled that of healthy controls.

Conclusions: Our findings indicated that plasma miR-150 and miR-342 are novel important promising biomarkers in the diagnosis of AML. These novel and promising markers warrant validation in larger prospective studies.

Citing Articles

Unveiling shared therapeutic targets and pathological pathways between coronary artery disease and major depressive disorder through bioinformatics analysis.

Hu M, Tan R, Lu C, Zhou T, Wang Q, Liu T Sci Rep. 2024; 14(1):29365.

PMID: 39592804 PMC: 11599718. DOI: 10.1038/s41598-024-80920-2.


Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.

Zdralevic M, Radovic A, Raonic J, Popovic N, Klisic A, Vuckovic L Int J Mol Sci. 2024; 25(20).

PMID: 39456841 PMC: 11507567. DOI: 10.3390/ijms252011060.


Mir-150-5p distinguishes acute pulmonary embolism, predicts the occurrence of pulmonary arterial hypertension, and regulates ox-LDL-induced endothelial cell injury.

Wu Y, Sun X, Cui G, Wang S Hereditas. 2024; 161(1):33.

PMID: 39256826 PMC: 11384695. DOI: 10.1186/s41065-024-00333-z.


Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.

Peng J, Lin Y, Sheng X, Yuan C, Wang Y, Yin W BMC Cancer. 2024; 24(1):789.

PMID: 38956544 PMC: 11221026. DOI: 10.1186/s12885-024-12500-6.


Liquid biopsies and minimal residual disease in myeloid malignancies.

Allam S, Nasr K, Khalid F, Shah Z, Khan Suheb M, Mulla S Front Oncol. 2023; 13:1164017.

PMID: 37213280 PMC: 10196237. DOI: 10.3389/fonc.2023.1164017.


References
1.
Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

2.
Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T . MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers. 2009; 14(7):529-38. DOI: 10.3109/13547500903150771. View

3.
Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

4.
Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

5.
Lawrie C, Gal S, Dunlop H, Pushkaran B, Liggins A, Pulford K . Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x. View